News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management

All Releases

09 December 2008 CSL Behring Awards Second Round of LEAD Grants in Support of Patient Group Advocacy Efforts

CSL Behring, a global leader in the plasma-protein biotherapies industry, announces the awarding of five grants totaling more than $65,000 to patient advocacy organizations in the United States. These five grants represent the second round of semi-annual awards in the company's Local Empowerment for Advocacy Development (LEAD) program. To date, the company has awarded more than $150,000 in grants through the LEAD program.

> Read More
19 November 2008 CSL Behring Launches GameFaces Program at National Hemophilia Foundation Annual Meeting

CSL Behring announced today it launched the first challenge of GamesFaces™, a family-oriented online initiative for patients with hemophilia A, at the 60th Annual Meeting of the National Hemophilia Foundation (NHF). GameFaces is designed to encourage real-life physical activity through a series of three customized challenges based on the individual’s age, disease severity and current level of physical activity. Participants can now log on to the program website at, create their GameFaces character and begin the first challenge, which will run from today through January 10, 2009.

> Read More
01 October 2008 Moms Raise "Red Flag" about the Dangers of Widely Undiagnosed Bleeding Disorder

National Campaign Highlights Signs, Symptoms, Impact on Families of von Willebrand Disease. A group of mothers with VWD have joined together to focus attention on the need for more communication between mothers and their children about signs, symptoms and potentially severe health consequences of this disease.

> Read More
30 September 2008 CSL Behring Initiating Next Round of LEAD Grants to Support Patient Advocacy Efforts

CSL Behring, a global leader in the plasma protein biotherapeutics industry, is soliciting grants to support patient access to care through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program is committed to funding grassroots advocacy efforts in the United States by providing grants to patient organizations dedicated to helping people with rare diseases who use plasma-derived or recombinant therapies to manage their conditions.

> Read More
25 September 2008 Data Published in Journal of Clinical Immunology Show Privigen™ Demonstrates Effectiveness and Tolerability in Patients with Primary Immunodeficiencies

New L-Proline Stabilized Immune Globulin Intravenous (Human) 10 Percent Liquid can be stored at room temperature, offering convenience to healthcare professionals

> Read More
Page 47 of 52 First | Previous | Next | Last

LinkedIn Twitter Facebook Google+